Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234310 · ClinicalTrials.gov registry record · Phase 3
Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B
A Phase 3 study, sponsored by Bioverativ, a Sanofi company.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT02234310 is a Phase 3 study that has completed, run by Bioverativ, a Sanofi company. The registered enrollment target is 33 participants.
The verdict
NCT02234310, a Phase 3 study, has completed, sponsored by Bioverativ, a Sanofi company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective of the study was to evaluate the safety of recombinant coagulation factor IX Fc fusion protein (rFIXFc, BIIB029) in previously untreated patients (PUPs) with severe hemophilia B. Secondary objectives were to evaluate the efficacy of rFIXFc in the prevention and treatment of bleeding episodes in PUPs, and to evaluate rFIXFc consumption for prevention and treatment of bleeding episodes in PUPs.
Interventions
- BIOLOGICAL rFIXFc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-11-13 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234310
The ClinicalTrials.gov registry entry for NCT02234310 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ, a Sanofi company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rFIXFc is the first listed.
NCT02234310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02234310 about?
NCT02234310 is a clinical study titled "Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B". The primary objective of the study was to evaluate the safety of recombinant coagulation factor IX Fc fusion protein (rFIXFc, BIIB029) in previously untreated patients (PUPs) with severe hemophilia B. Secondary objectives were to evaluate the efficacy of rFIXFc in the prevention and treatment of ble...
What is the current status of trial NCT02234310?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2014-11-13. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT02234310?
The interventions under investigation include: rFIXFc (BIOLOGICAL).
Who is sponsoring clinical trial NCT02234310?
This trial is sponsored by Bioverativ, a Sanofi company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.